采用CT和CA 19-9回顾性评估非转移性胰腺癌患者的治疗反应
本研究回顾性纳入197例接受一线化疗或同步放化疗的非转移性胰腺导管腺癌患者,于治疗后8周按RECIST标准评估CT反应并检测CA 19-9水平。整合CT与CA 19-9反应可将患者分为三组,中位总生存期分别为26.6个月、15.9个月和6.5个月,组间差异有统计学意义,提示联合评估较单纯RECIST能更准确地进行早期生存分层。
要点
- 治疗后8周CT示疾病进展者总生存期短于疾病稳定者和部分缓解者。
- 部分缓解与疾病稳定的总生存期无显著差异。
- CT与CA 19-9双应答者中位总生存期26.6个月,优于其他两组。
核心结论
- 整合CT与CA 19-9反应可在治疗早期对胰腺导管腺癌患者进行更准确的生存分层,优于单纯按RECIST标准评估。
研究设计与样本
- 单中心胰腺导管腺癌队列注册研究,回顾性纳入2013年1月至2016年12月接受一线化疗或同步放化疗的非转移性患者197例(平均年龄65岁±10,男107例),以治疗后8周随访CT按RECIST标准评估,并结合CA 19-9水平进行反应分组。
关键影像表现/征象
- CT示疾病进展者(n=17)总生存期短于疾病稳定者(n=147,P<.001)和部分缓解者(n=33,P=.003)。
- 部分缓解者与疾病稳定者总生存期无显著差异(P=.60)。
- CT与CA 19-9双应答组(第1组,n=27)中位总生存期26.6个月(95%CI:9.0,44.1)。
- CT应答但CA 19-9非应答组(第2组,n=153)中位总生存期15.9个月(95%CI:13.3,18.5),较第1组缩短(P=.007)。
- CT与CA 19-9双非应答组(第3组,n=17)中位总生存期6.5个月(95%CI:0.8,12.2),较第2组缩短(P<.001)。
诊断标准与关键数值
- CT应答定义为部分缓解(PR)或疾病稳定(SD),CT非应答定义为疾病进展(PD),按RECIST标准于治疗后8周评估。
- CA 19-9应答定义为8周随访时CA 19-9水平恢复正常,CA 19-9非应答定义为未恢复正常或未升高。
临床应用与阅片要点
- 治疗后8周联合CT与CA 19-9反应评估,有助于对非转移性胰腺导管腺癌患者进行早期生存分层。
- 仅凭RECIST评估时,部分缓解与疾病稳定的生存无显著差异,联合CA 19-9可进一步区分预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Imaging studies have limitations in evaluating pancreatic ductal adenocarcinoma (PDAC) treatment response. Purpose To investigate the effectiveness of combined CT and carbohydrate antigen 19-9 (CA 19-9) evaluation at 8 weeks after first-line treatment to predict overall survival (OS) of patients with nonmetastatic PDAC. Materials and Methods Patients with nonmetastatic PDAC who received first-line treatment with either chemotherapy or concurrent chemoradiation in a single-center PDAC cohort registry were retrospectively enrolled in the study between January 2013 and December 2016. Follow-up CT images obtained 8 weeks after treatment were evaluated according to Response Evaluation Criteria in Solid Tumors. Patients with partial response (PR) or stable disease (SD) were defined as CT responders, and those with progressive disease (PD) were defined as CT nonresponders. Patients with a normalized CA 19-9 level at 8-week follow-up were defined as CA 19-9 responders, and those with a nonnormalized or nonelevated CA 19-9 level were defined as CA 19-9 nonresponders. OS was compared using the Kaplan-Meier method with Breslow analysis. Results A total of 197 patients (mean age ± standard deviation, 65 years ± 10; 107 men) were evaluated. Patients with PD (n = 17) showed shorter OS than those with SD (n = 147; P < .001) or PR (n = 33; P = .003). OS did not differ between the patients with PR and those with SD (P = .60). When the CT and CA 19-9 responses were integrated, OS was longest in CT and CA 19-9 responders (group 1, n = 27; median OS, 26.6 months [95% CI: 9.0, 44.1]), followed by CT responders but CA 19-9 nonresponders (group 2, n = 153; median OS, 15.9 months [95% CI: 13.3, 18.5]; P = .007 vs group 1) and CT and CA 19-9 nonresponders (group 3, n = 17; median OS, 6.5 months [95% CI: 0.8, 12.2]; P < .001 vs group 2). Conclusion Integrated evaluation with CT and carbohydrate antigen 19-9 response allowed more accurate stratification of survival in patients with pancreatic ductal adenocarcinoma in the early treatment period than did evaluation according to Response Evaluation Criteria in Solid Tumors. © RSNA, 2022 Online supplemental material is available for this article.
引用
- Kim, Lee, Lee, et al. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Radiology. 2022. PMID: 35258374. doi:10.1148/radiol.212236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。